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Supplementary Results
Category Parameter Description
Assay Type of assay In vitro biochemical assay
Target Rpn11 (NCBI Protein ID: PSMD14; Gene ID: 10213)
Primary measurement Fluorescent Polarization
Key reagents Ub4-pepOG protein substrate, 26S proteasome from human 
erythrocytes 
Assay protocol See PubChem Bioassay: AID 588493 
(https://pubchem.ncbi.nlm.nih.gov/bioassay/588493)
In summary: uHTS Procedure
1) Using LabCyte Echo, transfer 40 nL of test compounds from a 2 mM
compound source plate into assay plate Cols. 5-48 (final concentration 
of test compounds is 20 uM, 1 % DMSO). Transfer 40 nL of 100% 
DMSO into assay plate Col. 1-4. 
2) Pre-incubate 20nM 26S proteasome in Epoxomicin Solution at room 
temperature for 1 hour, then dilute 10-fold in pre-chilled 1x Assay 
Buffer.
3) Using Beckman BiorapTR dispense 2uL of Assay Buffer in columns 
1 and 2, and 2uL of 26S proteasome solution to columns 3-48.
4) Using Beckman BiorapTR dispense 2ul of Ub4-pepOG substrate 
into all wells (columns 1-48)
5) Spin plates at 1500 rpm for 1 minute on Eppendorf centrifuge 5810.
6) Incubate for 80 minutes at room temp.
7) Read plates on Perkin Elmer Envision with dual mirror at Ex/Em
480/535 nm in fluorescent polarization mode
Library Library size 359.521
Source Molecular Libraries Small Molecules Repository Library (MLPCN, NIH)
Screen Format 1,536 Well Plate Format
Concentration(s) tested 20 µM
Reagent/ compound 
dispensing system
Labcyte Echo, Beckman Bioraptr
Detection instrument 
and software
PerkinElmer Envision
Assay validation/QC Z’=0.63, signal to background = 1.6 fold, signal to noise = 12.5 fold, 5.9 
signal window
Correction factors None
Normalization None
Post-HTS 
analysis
Hit criteria ≥ 40 % of inhibitory activity compared to the DMSO controls
Hit rate 0.55%
Additional assay(s) (1) Against an out-of-family thrombin metalloprotease for selectivity 
and possible interference with the fluorescence polarization readout. 
(AID:602333). (2) against MMP2 metalloprotease to exclude 
nonselective and potential likely Zn2+ chelators (AID:602330).
Supplementary Table 1.  Small molecule screening data
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Michaelis-Menten parameters
8TQ 10 μM 5 μM 2.5 μM 0
Vmax±S.E. 25.84±3.37 72.84±4.5 114.4±4.02 140.1±1.8
Km±S.E. 0.36±0.16 0.49±0.09 0.77±0.07 0.82±0.03
CZM 3.3 μM 1.7 μM 0.3 μM 0
Vmax±S.E. 63.81±4.05 106.3±1.19 139.5±3.37 172.7±3.29
Km±S.E. 0.41±0.12 0.66±0.03 0.80±0.07 1.03±0.07
Supplementary Table 2. 8TQ and Capzimin are uncompetitive inhibitors of Rpn11 
(proteasome holoenzyme)
Nature Chemical Biology: doi:10.1038/nchembio.2326
IC50 (μM) of Capzimin on other metalloenzymes
HDAC6 MMP 2 MMP 12 hCAII GLO1
>200 >50 >50 >50 42.8±2.2
Supplementary Table 3. Summary of Capzimin’s IC50 on metalloenzymes
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3021 IC50 (μM) CFZ IC50 (nM) Peptidase activity 
(LLVY-AMC)
HCT116 2.2 7.1 100%
Line 4 5.3 60 144%
Line 5 2.7 11 127%
Line 6 6.2 45 130%
Line 9 4.2 16 153%
Supplementary Table 4. A subset of 3021-resistant clones have elevated proteasome 
activity and increased resistance to carfilzomib.
Nature Chemical Biology: doi:10.1038/nchembio.2326
Antibody Vendor and catalog No. Applications
Ubiquitin pAb Enzo, ADI-SPA-200-F WB
Nrf2 Santa Cruz, sc-365949 WB
Cul1 Life Technologies, 32-2400 WB
Actin Santa Cruz, sc-1616 WB
Ubiquitin Santa Cruz, Sc-8017 IF
HDAC6 Cell Signaling, 7558S IF
SQSTM1 Santa Cruz, sc-25575 IF
HIF1 BD bioscience, 610959 WB
p53 Cell Signaling, 2524S WB
PERK Cell Signaling, 5683P WB
BiP Cell Signaling, 3177P WB
XBP1s BioLegend, 647502 WB
CHOP Cell Signaling, 2895P WB
DNAJB4 Santa Cruz, sc-100711 WB
GAPDH Santa Cruz, sc-25778 HRP WB
Supplementary Table 5. Antibodies used in this study
Nature Chemical Biology: doi:10.1038/nchembio.2326
Supplementary Figure 1
Supplementary Figure 1: Ub aldehyde has little effect on the kinetics of Ub4peptide
OG
cleavage. Shown are kinetic curves from the Rpn11 assay performed in the absence (black) or 
presence (red) of 1 µM Ub aldehyde.
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Supplementary Figure 2: Cleavage of Ub4peptide
OG requires ATP hyrolysis. The IC50 for 
inhibition of Rpn11 activity by non-hydrolyzable ATPγS was determined. Error bars represent s.d., 
n=4
Supplementary Figure 2
IC50=10.2 μM
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Supplementary Figure 3
Supplementary Figure 3: Structure of Zn(cyclen)2+
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Supplementary Figure 4: Capzimin does not alter cellular zinc. Cells were treated with 0.5%
DMSO (gray, n=11 cells), 50 µM TPA (black, n=12 cells), or CZM 10 µM (blue, n=11 cells) at
arrow 1. At arrow 2, TPA-treated cells were washed and treated with 0.75 µM pyrithione and 12
µM buffered zinc solution (Pyr/Zn).
Supplementary Figure 4
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Supplementary Figure 5: CZM is an uncompetitive inhibitor of Rpn11 (proteasome
holoenzyme), but a competitive inhibitor of AMSH and BRCC36. Shown are the Michaelis
Menten curves (a, c, e) or Lineweaver-Burke plots (b, d, f) of Rpn11 (a, b), AMSH (c, d) or
BRCC36 (e, f) activity assay in the presence of different concentrations of CZM. Error bars
represent s.d., n=3.
Supplementary Figure 5
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Supplementary Figure 6: Capzimin reversibly inhibits the proteasome in cells. Shown are 
fluorescence images of cells taken at different time points (as indicated) after treatment with 4μM of 
CZM or washout of CZM. 
1hr                    4hr      washout 3hr
1hr                    4hr      washout 3hr
field of view 1
field of view 2
Supplementary Figure 6
Nature Chemical Biology: doi:10.1038/nchembio.2326
Supplementary Figure 7: Capzimin is a reversible inhibitor in vitro. Shown is the fluorescence
polarization kinetics before and after 50X dilution. Before dilution, high concentration of CZM
(black) showed >80% inhibition of Rpn11 activity compared to DMSO control (red). After 50X
dilution, CZM (black) showed <10% inhibition of Rpn11 activity compared to the DMSO control
(orange). A pre-diluted sample (blue) with same concentration of proteasome and CZM served as
dilution control.
Supplementary Figure 7
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IC50=0.6±0.1 μM
Supplementary Figure 8
Supplementary Figure 8. Capzimin block the clearance of accumulated UbG76VGFP.The
degradation rate of UbG76V-GFP was measured at different concentrations of capzimin by
cycloheximide chase assay. Error bars represent s.d., n=3
Nature Chemical Biology: doi:10.1038/nchembio.2326
DMSO 3021
Supplementary Figure 9. 3021 has little effect on UbG76VGFP accumulation. Shown is
a fluorescence image of cells taken 4 hours after treatment with DMSO or 5 μM of 3021.
Supplementary Figure 9
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Supplementary Figure 10: Capzimin treatment induces accumulation of polyubiquitinated
species and Nrf2 in 293T cells. 293T cells were treated for 2 hours with different concentrations
(10 nM to 100 µM) of capzimin and cell lysates were fractionated by SDS-PAGE and
immunoblotted with antibodies against ubiquitin, Nrf2, Cul1 and actin, as indicated.
neddylated Cul1
unneddylated Cul1
Supplementary Figure 10
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Supplementary Figure 11: 3021 induces aggresome formation. A549 cells were 
treated with DMSO, 5 μM MG132 or 10 μM 3021 for 15 hours before being fixed and 
stained with antibodies against ubiquitin or p62/SQSTM1. 
DMSO   MG132                  3021
α- ubiquitin
α- p62/SQSTM1
Supplementary Figure 11
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MG132 (15 hrs)            DMSO                     8TQ
Supplementary Figure 12: 8TQ prevents the clearance of aggresomes. A549 cells were
treated with 5 μM MG132 for 15 hours to induce aggresome formation. MG132 was then washed
away. The cells were treated with DMSO or 5 μM 8TQ for 24 hours before being fixed and stained
with antibodies against ubiquitin, HDAC6, or SQSTM1.
Supplementary Figure 12
α- p62/SQSTM1
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10 μM
α- Ub
Supplementary Figure 13: 3021 prevents the clearance of aggresomes. A549 cells were
treated with 5 μM MG132 for 15 hours to induce aggresome formation. MG132 was then
washed away and cells were treated with DMSO or different concentration of 3021 for 24 hours
before being fixed and stained with antibodies against ubiquitin or SQSTM1.
Supplementary Figure 13
DMSO 0.5 μM 1 μM 10 μM
α- p62/SQSTM1
Nature Chemical Biology: doi:10.1038/nchembio.2326
α- PERK
α- BiP
α- XBP1s
α- CHOP
α- β actin
D
M
SO
2
 µ
M
1
0
 µ
M
B
TZ
C
B
5
0
8
3
Tu
n
ic
am
yc
in
Supplementary Figure 14: Capzimin induces an unfolded protein response in 293T
cells. 293T cells were treated for 8 hours with different concentrations of Capzimin (2 or 10
μM), BTZ (1 μM), the p97/VCP inhibitor CB5083 (10 μM), or Tunicamycin (2 μg/ml) and
cell lysates were fractionated by SDS-PAGE and immunoblotted with antibodies against
PERK, Bip, Xbp1s, CHOP and actin , as indicated.
CZM
Supplementary Figure 14
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Supplementary Figure 15: Summary of GI50 values from NCI60 screen. The average GI50 (3.3 µM)
was set to zero, and the sensitivity of individual cell types relative to the average is plotted on a linear
scale.
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Supplementary Figure 16: Cells lacking Nrf1 are more sensitive to 3021. WT (black) or
nfe2l1-/- MEF cells (red) were treated with different concentrations of 3021 for 72 hours and
then mixed with CellTiter-Glo reagent to quantify viable cells. Measured luminescence
values were normalized to DMSO control and data were fitted to a dose-response equation
to determine the GI50. Error bars represent s.d., n=3.
GI50 = 2.3 µM 
GI50 = 1.1 µM
Supplementary Figure 16
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Supplementary Figure 17: Comparison of the effects of CZM and BTZ treatment on
ubiquitination site occupancy and protein level. Venn diagram of the data from the
proteomic experiment, showing comparison of the effects of capzimin (orange) and bortezomib
(gray) on ubiquitination sites (a, b) and protein levels (c, d).
Supplementary Figure 17
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Supplementary Figure 18: Largest changes in ubiquitination site occupancy
upon treatment with Capzimin . Bar graphs of the data from the proteomic experiment,
showing the ubiquitination sites that showed the largest change in occupancy upon treatment
with capzimin. Top panel: sites with p-value ≤0.005. Bottom panel: sites with p-value between
0.05 and 0.005.
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Supplementary Figure 18
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Supplementary Figure 19: Largest changes in protein levels upon treatment with
capzimin. Bar graphs of the data from the proteomic experiment, showing the proteins that
showed the largest change in abundance upon treatment with capzimin. Top panel: proteins
that increased in level. Bottom panel: proteins that decreased in level. Yellow bars: proteins
with p-value ≤0.005. Red bars: proteins with p-value between 0.05 and 0.005.
P<0.005
0.05>P>=0.005
Supplementary Figure 19
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Supplementary Figure 20
Supplementary Figure 20: Capzimin promoted accumulation of DNAJB4. 293T cells were treated 
with different concentrations of capzimin (2 or 10 μM), BTZ (1 µM), CB5083 (10 µM), or Tunicamycin (2 
µg/ml) for 8 hrs. Western blot analyses were performed using antibodies against DNAJB4 and β-actin.
Nature Chemical Biology: doi:10.1038/nchembio.2326
Supplementary Figure 21
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Supplementary Figure 21: Full Western blot images
For Fig. 3d
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